Form 4: Catalyst Pharmaceuticals Director Acquires Shares and Stock Units

Director David S. Tierney of Catalyst Pharmaceuticals acquired options and restricted stock units on November 21, 2024, increasing his holdings in the company.

Summary

• David S. Tierney, a director at Catalyst Pharmaceuticals, acquired 23,248 options to purchase common stock at an exercise price of $21.12 on November 21, 2024.
• These options vest in three equal tranches on November 21, 2025, 2026, and 2027.
• Tierney also acquired 2,841 restricted stock units (RSUs) on the same date, which will convert to common stock upon vesting.
• Following these transactions, Tierney's direct holdings increased to 212,179 shares from options and 215,020 shares from RSUs.
• The transactions were reported on November 25, 2024.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as a director is increasing their stake in the company, which is generally seen as a good sign. However, it is a routine transaction and not a major event.

Positives

• The acquisition of shares and stock units by a director signals confidence in the company's future prospects.
• The vesting schedule of the options and RSUs aligns the director's interests with the long-term performance of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• The vesting schedule of the options and RSUs is typical for executive compensation packages in the pharmaceutical industry.
• The acquisition of shares by a director is a common practice and is often seen as a positive sign by investors.
• Similar filings are made by directors and officers of other pharmaceutical companies such as Amgen (AMGN) and Biogen (BIIB) when they acquire or dispose of company stock.

Stakeholder Impact

• The increased holdings by a director may positively influence investor confidence.
• The vesting schedule of the options and RSUs aligns the director's interests with the long-term performance of the company, which is beneficial for shareholders.

Key Dates

Keywords

Catalyst Pharmaceuticals, Director, David S. Tierney, Stock Options, Restricted Stock Units, Share Acquisition, Insider Trading, CPRX